Alucio™ is exclusively focused on serving the needs of the life science industry through the creative use of technology.
Our leadership team has had proven success delivering world-class software platforms and digital solutions to both large and small pharmaceutical, biotech and medical device companies. These range from pre-commercialization start-ups with single product candidates to well-established organizations with extensive product portfolios.
Our experience spans almost every therapeutic area including oncology, cardiology, infectious disease, neurology, rare disease, nephrology, dermatology, etc..
Our team's experience spans almost every therapeutic area including the below. Our product can also support MSL and field medical groups covering any disease state.
To further deepen our experience within the space and better understand customer needs, we have established an active product advisory board as a key company resource.
The Alucio Product Advisory Board (PAB) is made up of a cross-section of experienced life science professionals with relevant expertise in medical affairs and field medical positions within leading life science companies.
The PAB provides Alucio leadership with an industry viewpoint and end-user perspective on the company’s products, feature sets and future roadmaps. This guidance also includes actively communicating user needs, describing workflows and highlighting current market gaps that exist.
We are very fortunate to have this talented team of engaged industry professionals supporting our efforts.
Alucio regularly engages with end users and prospective customers to gather key insights regarding the world of medical affairs, MSLs, and other field medical professionals. Our initial product, Beacon, has been specifically developed and tailored to support these audiences. Here are some representative quotes from leading professionals in these roles from across the industry which speak to our goal of “supercharging scientific exchange”.
“Alucio is creating an innovative solution to the medical content challenges and inefficiencies that pharma field medical teams face today.”